Skip to main content

Table 1 Baseline characteristics of patients with Crohn’s disease (CD) and Ulcerative colitis (UC)

From: Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study

 

Patients with CD

Patients with UC

Disease duration from initial diagnosis (years)

12.9 (0.5–44.3)

8.3 (0.1–51.3)

Age at initial diagnosis (years)

25.5 (10.5–66.8)

34 (4.0–77.3)

Female (%)

47/75 (63)

46/106 (43)

CRP (mg/L)

11 (0.2–78.3)

8.5 (0.2–62.8)

Hb (g/dL)

12.9 (9.1–16.5)

12.7 (7.5–16.8)

Leukocytes × 103/µL

9.9 (3.6–20)

9.3 (2.4–22.5)

Endoscopic disease activity*

13.3 (0–26)

2.3 (0–3)

Clinical disease activity**

7.03 (0–22)

4 (0–8)

Disease extent (%)***

L1: 15/75 (20)

E1: 7/104 (7)

L2: 10/75 (13)

E2: 51/104 (49)

L3: 50/75 (67)

E3: 46/104 (44)

First flare treated with corticosteroids (%)

63/73 (86)

86/102 (84)

Previous treatment with anti TNF-α antibody (%)

67/75 (89)

79/105 (75)

Number of previous anti TNF-α antibodies (%)

1: 14/67 (21)

1: 43/79 (54)

2: 52/67 (78)

2: 31/79 (39)

3: 1/67 (1)

3: 5/79 (6)

Active smoking (%)

21/75 (28)

8/105 (8)

Concomitant corticosteroid therapy (%)

42/74 (57)

53/101 (52)

Concomitant immunosuppressant use (%)

Azathioprin: 3/74 (4)

Azathioprin: 6/102 (6)

6-Mercaptopurin: 0/74 (0)

6-Mercaptopurin: 2/102 (2)

MTX: 5/74 (7)

MTX: 0/102 (0)

Prior bowel surgery (%)

22/75 (29)

1/106 (1)

CD phenotype*** (%)

B1: 18/75 (24)

 

B2: 30/75 (40)

 

B3: 27/75 (36)

 

Extraintestinal manifestations (%)

25/75 (33)

14/106 (13)

  1. Data are presented as mean (minimal value—maximal value) or frequencies (%)
  2. *Endoscopic Mayo score for UC, simplified endoscopic score for Crohn’s disease (SES-CD) for CD
  3. **PMS (partial Mayo score) for UC, HBI (Harvey Bradshaw-Index) for CD
  4. ***According to the Montreal classification